Electrophoretic karyotyping and triazole susceptibility of Candida glabrata clinical isolates

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 18, Issue 3, 1999, Pages 184-187

  Barchiesi, F ^a   Falconi Di Francesco, L ^a   Arzeni, D ^a   Caselli, F ^a   Gallo, D ^a   Scalise, G ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; TRIAZOLE;

ARTICLE; CANDIDA GLABRATA; CLINICAL ARTICLE; DRUG SENSITIVITY; ELECTROPHORESIS; HUMAN; KARYOTYPING; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; STRAIN DIFFERENCE;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DNA, FUNGAL; DRUG RESISTANCE, MICROBIAL; FLUCONAZOLE; HUMANS; ITRACONAZOLE; KARYOTYPING; MICROBIAL SENSITIVITY TESTS;

EID: 0032700780     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100960050255     Document Type: Article

References (13)

1. 1. Nguyen MH, Peacock JE, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, Wagener MM, Rinaldi MG, Yu VL: The changing face of candidemia: emergence of non Candida albicans species and antifungal resistance. American Journal of Medicine (1996) 100:617-623
2. 2. Anaissie E: Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clinical Infectious Diseases (1992) 14, Supplement 1:43-53
3. 3. Rex JH, Rinaldi MG, Pfaller MA: Resistance of Candida species to fluconazole. Antimicrobial Agents and Chemotherapy (1995) 39:1-8
4. 4. Cormican MG, Hollis RJ, Pfaller MA: DNA macrorestriction profiles and antifungal susceptibility of Candida (Torulopsis) glabrata. Diagnostic Microbiology and Infectious Disease (1996) 2:83-87
5. 5. Kaufmann CS, Merz WG: Electrophoretic karyotypes of Torulopsis glabrata. Journal of Clinical Microbiology (1989) 27:2165-2168
6. 6. Vazquez JA, Beckley A, Donabedian S, Sobel JD, Zervos MJ: Comparison of restriction enzyme analysis versus pulsed field gradient gel electrophoresis as a typing system for Torulopsis glabrata and Candida species other than C. albicans. Journal of Clinical Microbiology (1993) 31:2021-2030
7. 7. Warren NG, Shadomy HJ: Yeasts of medical importance. In: Balows A, Hausler WJ Jr, Herrmann KL, Isenberg HD, Shadomy HJ (eds): Manual of clinical microbiology. American Society for Microbiology, Washington DC (1991), pp. 617-629
8. 8. Barchiesi F, Arzeni D, Del Prete MS, Sinicco A, Falconi Di Francesco L, Pasticci MB, Lamura L, Nuzzo MM, Burzacchini F, Coppola S, Chiodo F, Scalise G: Fluconazole susceptibility and strain variation of Candida albicans isolates from HIV-infected patients with oropharyngeal candidosis. Journal of Antimicobial Chemotherapy (1998) 41:541-548
9. 9. Sneath PHA: Numerical taxonomy. In: Sneath PHA, Sokal RR (eds): The principles and practice of numerical classification. Freeman WH, San Francisco (1973) pp. 230-234
10. 10. National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. NCCLS, Wayne, PA (1997)
11. 11. Barchiesi F, Falconi Di Francesco L, Scalise G: In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles. Antimicrobial Agents and Chemotherapy (1997) 41:1812-1814
12. 12. Barchiesi F, Hollis RJ, McGough DA, Scalise G, Rinaldi MG, Pfaller MA: DNA subtypes and fluconazole susceptibilities of Candida albicans isolates from the oral cavities of patients with AIDS. Clinical Infectious Diseases (1995) 20:634-640
13. 13. Pfaller MA, Rhine-Chalberg J, Redding SW, Smith J, Farinacci G, Fothergill AW, Rinaldi MA: Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. Journal of Clinical Microbiology (1994) 32:59-64